"Dr. Mojsov's legacy of groundbreaking and transformative work is a testament to her dedication and brilliance," said Eric G. Neilson, MD, Lewis Landsberg Dean and Vice President for Medical Affairs. "She is an extraordinary scientist whose career in the laboratory has had a profound impact on human heath globally, and we are proud to recognize her with the 2026 Kimberly Prize."
"We are delighted to select Dr. Mojsov as the 2026 Kimberly Prize winner for her pioneering discoveries and contributions on GLP-1. Her studies have transformed our understanding of peptide hormones and laid the foundation for life-changing therapies for type 2 diabetes and obesity," said Ali Shilatifard, PhD, the chair and Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics, and director of the Simpson Querrey Institute for Epigenetics, which awards the annual Kimberly Prize."
"From early peptide synthesis to uncovering GLP-1's incretin role, her impactful studies bridge fundamental science and clinical medicine. Dr. Mojsov's legacy exemplifies the complete arc of discovery to global impact, embodying the spirit of the Kimb"
Northwestern University Feinberg School of Medicine and the Simpson Querrey Institute for Epigenetics awarded Svetlana Mojsov the $250,000 Kimberly Prize. Mojsov discovered glucagon-like peptide 1 (GLP-1), an incretin hormone produced by gut tissue that regulates insulin secretion and glucose metabolism. Her discovery translated into widely used treatments for type 2 diabetes and weight loss. Planned engagements include a public lecture in Chicago, meetings with faculty, fellows, and students, and an award dinner in spring 2026. Her research spanned peptide synthesis to defining GLP-1's clinical role, linking basic biochemistry to transformative medical therapies.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]